| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.270.2.843 |
| P698 | PubMed publication ID | 7822320 |
| P2093 | author name string | Clarke DM | |
| Loo TW | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 843-848 | |
| P577 | publication date | 1995-01-01 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Membrane topology of a cysteine-less mutant of human P-glycoprotein | |
| P478 | volume | 270 |
| Q73697352 | A model for the topology of excitatory amino acid transporters determined by the extracellular accessibility of substituted cysteines |
| Q39681554 | A novel MDR1 GT1292-3TG (Cys431Leu) genetic variation and its effect on P-glycoprotein biologic functions |
| Q28138314 | A novel topology model of the human Na(+)/H(+) exchanger isoform 1 |
| Q39302228 | A plausible explanation for enhanced bioavailability of P-gp substrates in presence of piperine: simulation for next generation of P-gp inhibitors. |
| Q42666847 | A single membrane-embedded negative charge is critical for recognizing positively charged drugs by the Escherichia coli multidrug resistance protein MdfA. |
| Q33832047 | A structure-based mechanism for drug binding by multidrug transporters |
| Q30375556 | A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. |
| Q41934653 | Agrobacterium tumefaciens VirB6 domains direct the ordered export of a DNA substrate through a type IV secretion System |
| Q58449731 | Amino acid substitutions in the first transmembrane domain (TM1) of P-glycoprotein that alter substrate specificity |
| Q42048612 | Analysis of the membrane topology for transmembrane domains 7-12 of the human reduced folate carrier by scanning cysteine accessibility methods |
| Q40380547 | Aquaporin water channels: unanswered questions and unresolved controversies |
| Q42018301 | Bio-layer interferometry for measuring kinetics of protein-protein interactions and allosteric ligand effects. |
| Q48377837 | Biotinylation of single cysteine mutants of the glutamate transporter GLT-1 from rat brain reveals its unusual topology |
| Q22008045 | Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins |
| Q38354623 | Characterization of a cysteine-less human reduced folate carrier: localization of a substrate-binding domain by cysteine-scanning mutagenesis and cysteine accessibility methods |
| Q71546979 | Co-translational effects of temperature on membrane insertion and orientation of P-glycoprotein sequences |
| Q36018435 | Combination of curcumin and piperine prevents formation of gallstones in C57BL6 mice fed on lithogenic diet: whether NPC1L1/SREBP2 participates in this process? |
| Q57971444 | Comparative Topology Studies inSaccharomyces cerevisiaeand inEscherichia coli |
| Q41067952 | Conformational changes of P-glycoprotein by nucleotide binding |
| Q37362505 | Conserved Walker A cysteines 431 and 1074 in human P-glycoprotein are accessible to thiol-specific agents in the apo and ADP-vanadate trapped conformations |
| Q53911158 | Conserved walker A Ser residues in the catalytic sites of P-glycoprotein are critical for catalysis and involved primarily at the transition state step. |
| Q36910362 | Coupled translocation events generate topological heterogeneity at the endoplasmic reticulum membrane |
| Q41293154 | Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity |
| Q40795985 | Cross-linking of human multidrug resistance P-glycoprotein by the substrate, tris-(2-maleimidoethyl)amine, is altered by ATP hydrolysis. Evidence for rotation of a transmembrane helix. |
| Q34177343 | Cysteine residues in the nucleotide binding domains regulate the conductance state of CFTR channels |
| Q54041684 | Cysteine-scanning mutagenesis of transmembrane segments 4 and 5 of the Tn10-encoded metal-tetracycline/H+ antiporter reveals a permeability barrier in the middle of a transmembrane water-filled channel. |
| Q43610789 | Cysteines 431 and 1074 are responsible for inhibitory disulfide cross-linking between the two nucleotide-binding sites in human P-glycoprotein |
| Q38972586 | Cysteines introduced into extracellular loops 1 and 4 of human P-glycoprotein that are close only in the open conformation spontaneously form a disulfide bond that inhibits drug efflux and ATPase activity. |
| Q43560244 | Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil |
| Q28366017 | Detailed characterization of cysteine-less P-glycoprotein reveals subtle pharmacological differences in function from wild-type protein |
| Q43717027 | Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers |
| Q33784435 | Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques |
| Q33802134 | Directed evolution of P-glycoprotein cysteines reveals site-specific, non-conservative substitutions that preserve multidrug resistance. |
| Q38611122 | Dissection of de novo membrane insertion activities of internal transmembrane segments of ATP-binding-cassette transporters: toward understanding topological rules for membrane assembly of polytopic membrane proteins |
| Q40608295 | Disulfide cross-linking analysis shows that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the cytoplasmic side of the membrane |
| Q33185124 | Drug binding in human P-glycoprotein causes conformational changes in both nucleotide-binding domains. |
| Q36578713 | Drug-protein hydrogen bonds govern the inhibition of the ATP hydrolysis of the multidrug transporter P-glycoprotein |
| Q57976942 | Drug-stimulated ATPase Activity of Human P-glycoprotein Requires Movement between Transmembrane Segments 6 and 12 |
| Q40880583 | Drug-stimulated ATPase activity of human P-glycoprotein is blocked by disulfide cross-linking between the nucleotide-binding sites. |
| Q38808182 | Effect of Liver Disease on Hepatic Transporter Expression and Function |
| Q37076043 | Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2. |
| Q58449698 | Effects of Ala Substitution for Conserved Cys Residues in Mouse Ileal and Hepatic Na+-Dependent Bile Acid Transporters |
| Q54583341 | Enzymatic and biochemical probes of residues external to the translocation pathway of UhpT, the sugar phosphate carrier of Escherichia coli. |
| Q37705351 | Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation |
| Q42421298 | Evidence for VirB4-mediated dislocation of membrane-integrated VirB2 pilin during biogenesis of the Agrobacterium VirB/VirD4 type IV secretion system |
| Q30153385 | Evidence supporting the 19 β-strand model for Tom40 from cysteine scanning and protease site accessibility studies |
| Q36277561 | Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein |
| Q30821215 | Function of the transport complex TAP in cellular immune recognition |
| Q33991448 | Functional importance and local environments of the cysteines in the tetracycline resistance protein encoded by plasmid pBR322. |
| Q33283772 | Genetic selection for a highly functional cysteine-less membrane protein using site saturation mutagenesis |
| Q32133639 | Genetic separation of FK506 susceptibility and drug transport in the yeast Pdr5 ATP-binding cassette multidrug resistance transporter. |
| Q43588594 | Identification and localization of three photobinding sites of iodoarylazidoprazosin in hamster P-glycoprotein |
| Q57976933 | Identification of Residues in the Drug-binding Domain of Human P-glycoprotein |
| Q57976930 | Identification of Residues within the Drug-binding Domain of the Human Multidrug Resistance P-glycoprotein by Cysteine-scanning Mutagenesis and Reaction with Dibromobimane |
| Q36883283 | In vivo kinetics of protein targeting to the endoplasmic reticulum determined by site-specific phosphorylation |
| Q54450403 | In vivo membrane topology of Escherichia coli SecA ATPase reveals extensive periplasmic exposure of multiple functionally important domains clustering on one face of SecA. |
| Q38774272 | In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer |
| Q57976949 | Inhibition of Oxidative Cross-linking between Engineered Cysteine Residues at Positions 332 in Predicted Transmembrane Segments (TM) 6 and 975 in Predicted TM12 of Human P-glycoprotein by Drug Substrates |
| Q33784443 | Insights into the structure and substrate interactions of the P-glycoprotein multidrug transporter from spectroscopic studies |
| Q40724271 | Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments. |
| Q77754745 | Investigation of the extracellular accessibility of the connecting loop between membrane domains I and II of the bradykinin B2 receptor |
| Q43999359 | Ischemia-reperfusion-inducible protein modulates cell sensitivity to anticancer drugs by regulating activity of efflux transporter |
| Q33864499 | Ligand-mediated tertiary structure changes of reconstituted P-glycoprotein. A tryptophan fluorescence quenching analysis |
| Q34868733 | Lipids and topological rules of membrane protein assembly: balance between long and short range lipid-protein interactions. |
| Q28386214 | Lipids in the assembly of membrane proteins and organization of protein supercomplexes: implications for lipid-linked disorders |
| Q34444820 | Localization of a substrate binding domain of the human reduced folate carrier to transmembrane domain 11 by radioaffinity labeling and cysteine-substituted accessibility methods |
| Q40704865 | Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. |
| Q41848364 | Locking intracellular helices 2 and 3 together inactivates human P-glycoprotein. |
| Q43099273 | Mapping the Binding Site of the Inhibitor Tariquidar That Stabilizes the First Transmembrane Domain of P-glycoprotein. |
| Q30481309 | Mapping the membrane-aqueous border for the voltage-sensing domain of a potassium channel |
| Q54080962 | Mapping the substrate binding site of the prostaglandin transporter PGT by cysteine scanning mutagenesis. |
| Q42064287 | Membrane topology and glycosylation of the human multidrug resistance-associated protein |
| Q30326361 | Membrane topology and insertion of membrane proteins: search for topogenic signals |
| Q44495023 | Membrane topology of ABC-type macrolide antibiotic exporter MacB in Escherichia coli |
| Q47954696 | Membrane topology of subunit a of the F1F0 ATP synthase as determined by labeling of unique cysteine residues |
| Q54567476 | Membrane topology of the ATP-binding cassette transporter associated with antigen presentation (Tap1) expressed in Escherichia coli. |
| Q28256996 | Membrane topology of the DrrB protein of the doxorubicin transporter of Streptomyces peucetius |
| Q71973472 | Membrane topology of the transposon 10-encoded metal-tetracycline/H+ antiporter as studied by site-directed chemical labeling |
| Q33699333 | Merck Frosst Award Lecture 1998. Molecular dissection of the human multidrug resistance P-glycoprotein |
| Q33193592 | Methanethiosulfonate derivatives of rhodamine and verapamil activate human P-glycoprotein at different sites |
| Q37323494 | Molecular analysis of the multidrug transporter, P-glycoprotein |
| Q38339772 | Molecular basis of the polyspecificity of P-glycoprotein (ABCB1): recent biochemical and structural studies |
| Q28536673 | Multiple transport-active binding sites are available for a single substrate on human P-glycoprotein (ABCB1) |
| Q57976952 | Mutational Analysis of the Predicted First Transmembrane Segment of Each Homologous Half of Human P-glycoprotein Suggests That They Are Symmetrically Arranged in the Membrane |
| Q37763152 | Nanomedicinal strategies to treat multidrug-resistant tumors: current progress |
| Q39638448 | Neither P-gp SNP variants, P-gp expression nor functional P-gp activity predicts MDR in a preliminary study of plasma cell myeloma. |
| Q35000267 | New structural arrangement of the extracellular regions of the phosphate transporter SLC20A1, the receptor for gibbon ape leukemia virus |
| Q46416788 | Nucleotide-induced structural changes in P-glycoprotein observed by electron microscopy. |
| Q41295494 | P-glycoprotein. Associations between domains and between domains and molecular chaperones |
| Q40652649 | Permanent Activation of the Human P-glycoprotein by Covalent Modification of a Residue in the Drug-binding Site |
| Q46487770 | Phospholipids as determinants of membrane protein topology. Phosphatidylethanolamine is required for the proper topological organization of the gamma-aminobutyric acid permease (GabP) of Escherichia coli |
| Q33881741 | Plant ABC transporters |
| Q44020847 | Probing the membrane topology of a subunit of the mitochondrial protein translocase, Tim44, with biotin maleimide |
| Q41993227 | Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR). |
| Q40537131 | Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains. |
| Q26777721 | Providing a molecular mechanism for P-glycoprotein; why would I bother? |
| Q34811676 | Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. |
| Q36386127 | Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. |
| Q24535845 | Repacking of the transmembrane domains of P-glycoprotein during the transport ATPase cycle |
| Q44485456 | Reversal of P-glycoprotein expressed in Escherichia coli leaky mutant by ascorbic acid |
| Q44606581 | Reversible topological organization within a polytopic membrane protein is governed by a change in membrane phospholipid composition |
| Q37383200 | Sequence requirements for membrane assembly of polytopic membrane proteins: molecular dissection of the membrane insertion process and topogenesis of the human MDR3 P-glycoprotein |
| Q48313444 | Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). |
| Q44543802 | Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein |
| Q36349672 | Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition |
| Q45325135 | Site Specific Modification of Adeno-Associated Virus Enables Both Fluorescent Imaging of Viral Particles and Characterization of the Capsid Interactome. |
| Q46142975 | Site-specific incorporation of biotinylated amino acids to identify surface-exposed residues in integral membrane proteins |
| Q44138744 | Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1. |
| Q40469656 | Structural requirements of the extracellular to transmembrane domain junction for erythropoietin receptor function. |
| Q28216421 | Structure and association of ATP-binding cassette transporter nucleotide-binding domains |
| Q34657202 | Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter |
| Q53970603 | Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. |
| Q40667534 | Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. |
| Q40082401 | Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites. |
| Q44133854 | The "LSGGQ" motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing walker A sequence |
| Q36137412 | The ATPase activity of the P-glycoprotein drug pump is highly activated when the N-terminal and central regions of the nucleotide-binding domains are linked closely together |
| Q39568449 | The SecA subunit of Escherichia coli preprotein translocase is exposed to the periplasm |
| Q46696937 | The active site His-460 of human acyl-coenzyme A:cholesterol acyltransferase 1 resides in a hitherto undisclosed transmembrane domain |
| Q36298510 | The chloroplast twin arginine transport (Tat) component, Tha4, undergoes conformational changes leading to Tat protein transport |
| Q40492449 | The dileucine motif at the COOH terminus of human multidrug resistance P-glycoprotein is important for folding but not activity |
| Q77926901 | The membrane topology of proton-pumping Escherichia coli transhydrogenase determined by cysteine labeling |
| Q41155410 | The minimum functional unit of human P-glycoprotein appears to be a monomer. |
| Q41881683 | The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction. |
| Q34313553 | The multi-structural feature of the multidrug resistance gene product P-glycoprotein: implications for its mechanism of action (hypothesis). |
| Q40899411 | The packing of the transmembrane segments of human multidrug resistance P-glycoprotein is revealed by disulfide cross-linking analysis. |
| Q34221144 | The region between transmembrane domains 1 and 2 of the reduced folate carrier forms part of the substrate-binding pocket |
| Q40934272 | The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. |
| Q28214433 | The transporter associated with antigen processing: function and implications in human diseases |
| Q51822776 | Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. |
| Q41890183 | Topology of AspT, the aspartate:alanine antiporter of Tetragenococcus halophilus, determined by site-directed fluorescence labeling |
| Q33995996 | Topology of OxlT, the oxalate transporter of Oxalobacter formigenes, determined by site-directed fluorescence labeling |
| Q54559159 | Topology of the integral membrane form of Escherichia coli SecA protein reveals multiple periplasmically exposed regions and modulation by ATP binding. |
| Q30160828 | Topology of the outer membrane usher PapC determined by site-directed fluorescence labeling |
| Q38358911 | Transmembrane organization of mouse P-glycoprotein determined by epitope insertion and immunofluorescence |
| Q33922207 | Transmembrane protein topology mapping by the substituted cysteine accessibility method (SCAM(TM)): application to lipid-specific membrane protein topogenesis |
| Q40313463 | Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket |
| Q38663320 | Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket |
| Q36663768 | Transmembrane topology of a CLC chloride channel |
| Q43730384 | Transmembrane topology of the sulfonylurea receptor SUR1. |
| Q44746508 | Val133 and Cys137 in transmembrane segment 2 are close to Arg935 and Gly939 in transmembrane segment 11 of human P-glycoprotein |
| Q34018799 | Vanadate trapping of nucleotide at the ATP-binding sites of human multidrug resistance P-glycoprotein exposes different residues to the drug-binding site |
Search more.